SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia

Verstovsek, S; Komatsu, N; Gill, H; Jin, J; Lee, SE; Hou, HA; Sato, T; Qin, A; Urbanski, R; Shih, WC; Zagrijtschuk, O; Zimmerman, C; Mesa, RA

Verstovsek, S (通讯作者)，MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.

FUTURE ONCOLOGY, 2022; 18 (27): 2999

Abstract

Patients diagnosed with high-risk essential thrombocythemia (ET) have limited treatment options to reduce the risk of thrombosis and lessen the progre......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索